Xencor initiates Phase 1 trial for XmAb541 and XmAb808 in advanced solid tumors
Xencor, Inc. has launched Phase 1 study to assess the safety and tolerability of XmAb541 and XmAb808 in patients with advanced solid tumors.
Company
Pharmaceutical intelligence for XmAb541 with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No signals indexed for this entity yet.
No signals indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.